Protective Effect of Transient Receptor Potential Ankyrin 1 Inhibition on Renal Ischemia Reperfusion Injury in Rats

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Transient receptor potential ankyrin 1 (TRPA1) channels are involved in sensing oxidative stress and are upregulated in renal ischemia-reperfusion (IR) injury.
• TRPA1 expression correlates with the severity of IR-induced renal damage.

Purpose of the Study:

• To investigate the therapeutic potential of TRPA1 modulation in a rat model of renal IR injury.
• To evaluate the effects of a TRPA1 agonist (ASP7663) and antagonist (HC-030031) on kidney damage markers and inflammatory pathways.

Main Methods:

• Rats underwent 45 minutes of renal ischemia followed by 24 hours of reperfusion.
• Animals were treated with either saline (control), ASP7663, or HC-030031.
• Kidney injury markers (KIM-1, BUN, creatinine), histopathology, and levels of inflammatory mediators (IL-1β, IL-6, TNF-α) and apoptosis markers (caspase-3) were assessed.

Main Results:

• Administration of the TRPA1 antagonist HC-030031 significantly reduced elevated KIM-1, BUN, and creatinine levels.
• HC-030031 treatment attenuated IR-induced histopathological damage in renal tissue.
• HC-030031 decreased the expression of IL-1β, IL-6, TLR-4, p-NF-κB, p-IκB-α, TNF-α, and caspase-3, indicating reduced inflammation and apoptosis.

Conclusions:

• TRPA1 antagonist HC-030031 demonstrates a protective effect against renal IR injury.
• HC-030031 mitigates renal damage by suppressing inflammatory and apoptotic pathways.
• TRPA1 inhibition presents a promising therapeutic target for preventing renal IR injury.